Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [31] Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting
    Sheikh, Fareeha
    Nazir, Adil
    Yasmeen, Samia
    Badar, Farhana
    Ahmad, Usman
    Siddiqui, Neelam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 159 - 163
  • [32] Primary Trastuzumab Resistance After (Neo) adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice
    Chen, Xuelian
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Zhang, Pin
    Li, Qing
    Ma, Fei
    Yuan, Peng
    Chen, Shanshan
    Li, Qiao
    Cai, Ruigang
    Xu, Binghe
    CLINICAL BREAST CANCER, 2021, 21 (03) : 191 - 198
  • [33] Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2-Positive Breast Cancer Patient Population
    Grela-Wojewoda, Aleksandra
    Puskulluoglu, Miroslawa
    Sas-Korczynska, Beata
    Zemelka, Tomasz
    Pacholczak-Madej, Renata
    Wysocki, Wojciech M.
    Wojewoda, Tomasz
    Adamczyk, Agnieszka
    Lompart, Joanna
    Korman, Michal
    Mucha-Malecka, Anna
    Ziobro, Marek
    Konduracka, Ewa
    CANCERS, 2022, 14 (14)
  • [34] Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
    Kim, In-Ho
    Lee, Ji Eun
    Youn, Ho-Joong
    Song, Byung Joo
    Chae, Byung Joo
    JOURNAL OF BREAST CANCER, 2017, 20 (01) : 82 - 90
  • [35] Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancerThe best of ASCO 2019
    Christoph Suppan
    Marija Balic
    memo - Magazine of European Medical Oncology, 2019, 12 : 312 - 314
  • [36] How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
    Morganti, S.
    Bianchini, G.
    Giordano, A.
    Giuliano, M.
    Curigliano, G.
    Criscitiello, C.
    ESMO OPEN, 2022, 7 (02)
  • [37] HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective
    Swati Kulkarni
    David G. Hicks
    Annals of Surgical Oncology, 2008, 15 : 1677 - 1688
  • [38] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [39] HER2-Positive early breast cancer and trastuzumab: A surgeon's perspective
    Kulkarni, Swati
    Hicks, David G.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) : 1677 - 1688
  • [40] Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer
    Neugut, Alfred I.
    Hillyer, Grace Clarke
    Kushi, Lawrence H.
    Lamerato, Lois
    Leoce, Nicole
    Ambrosone, Christine B.
    Bovbjerg, Dana H.
    Mandelblatt, Jeanne S.
    Hershman, Dawn L.
    BREAST CANCER, 2014, 21 (06) : 780 - 785
12345